Fusion Pharmaceuticals, Inc. (FUSN)
| Market Cap | 345.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -85.64M |
| Shares Out | 42.93M |
| EPS (ttm) | -2.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $8.21 |
| Previous Close | $7.95 |
| Change ($) | 0.26 |
| Change (%) | 3.27% |
| Day's Open | 7.98 |
| Day's Range | 7.86 - 8.21 |
| Day's Volume | 12,690 |
| 52-Week Range | 6.61 - 14.31 |
HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...
HAMILTON, Ontario and BOSTON , July 7, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pr...
Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug ...
HAMILTON, ON and BOSTON, June 7, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...
HAMILTON, ON and BOSTON, June 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...
HAMILTON, ON and BOSTON, May 27, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...
Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions HAMILTON, ON and B...
Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion's lead candidate, FPI-1434, in combination with Merck's Keytruda ...
HAMILTON, ON and BOSTON, May 6, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...
HAMILTON, ON and BOSTON, April 14, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...
Product candidate FPI-1434, when administered with olaparib, resulted in enhanced efficacy against colorectal and lung cancer xenografts Combination of IGF-1R targeted alpha therapy with immune checkpoi...
HAMILTON, ON and BOSTON, April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...
HAMILTON, ON and BOSTON, April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...
- FPI-1434 Phase 1 study is progressing - Recent transactions and partnerships expand and diversify Fusion's pipeline of targeted alpha therapies in development to treat a broad array of tumor types HAM...
HAMILTON, ON and BOSTON, Feb. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...
VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) -- TRIUMF, Canada's particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc...
Phase 1 Single-Dose Data Show Uptake Across Multiple Tumor Types; No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events HAMILTON, ON and BOSTON, Dec. 10, 2020 /PRNewswire/ -- Fusion Ph...
Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
HAMILTON, Ontario and BOSTON, Nov. 12, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pr...
HAMILTON, ON and BOSTON, Nov. 2, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...
Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies Fusion to Host a Conference Call at 8:30am ET...
HAMILTON, ON and BOSTON, Sept. 29, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...
- Following Fusion's June 2020 initial public offering, cash runway extended into 2024 HAMILTON, ON and BOSTON, Aug. 11, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc.
HAMILTON, ON and BOSTON, June 25, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...
The initial public offering of Fusion Pharmaceuticals receiving strong interest from investors as the biotech company increased the deal size. The Fusion Pharmaceuticals IPO trades Friday.
About FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors express... [Read more...]
| Industry Biotechnology | IPO Date Jun 26, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol FUSN |
Analyst Forecasts
According to 5 analysts, the average rating for FUSN stock is "Strong Buy." The 12-month stock price forecast is 22.25, which is an increase of 171.01% from the latest price.